Breathing Labs
Home
How To Start
Products
Breathing+ Package
Toys Package
Q&A
Login

Idiopathic Pulmonary Fibrosis

22Nov

Interferon Gamma APC Antibody (GWB-B51085)

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Interferon Gamma APC Antibody (GWB-B51085)

[*] Name Interferon Gamma APC Antibody (GWB-B51085) Related Product Names MOUSE ANTI HUMAN INTERFERON GAMMA: APC IFN GAMMA Gene Symbol IFNG Gene Family IFN Gene id 3458 Alias Symbols IFG, IFI, IFNG Swissprot ID P01579 Protein Name Interferon gamma Description of Target MOUSE ANTI HUMAN INTERFERON GAMMA:APC Protein Accession Num NP_000610.2 Clone B27 Application Info […]

Read more
22Nov

A randomized phase II study comparing four different interferon therapies in patients with recalcitrant condylomata acuminata.

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on A randomized phase II study comparing four different interferon therapies in patients with recalcitrant condylomata acuminata.

Sexually transmitted diseases.1998 Aug 4. A randomized phase II study comparing four different interferon therapies in patients with recalcitrant condylomata acuminata. Background Interferon (IFN) alpha and IFN gamma have synergistic in vitro and in vivo effects and have each been used in the treatment of anogenital condylomata acuminata. Objective To compare the efficacy and safety […]

Read more
20Nov

Pirfenidone IP 200 MG Wholesaler,Pirfenidone IP 200 MG Supplier, Exporter

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Pirfenidone IP 200 MG Wholesaler,Pirfenidone IP 200 MG Supplier, Exporter

USES : Pirfenidone is used to treat a certain lung disease called idiopathic pulmonary fibrosis (IPF). This disease causes the lungs to get scarred and become stiff, making it hard to breathe. Pirfenidone may help slow down the worsening of your IPF. SIDE EFFECTS : Tiredness, lack of energy, loss of appetite, weight loss, or changes in taste may occur. Dizziness, nausea, upset stomach, vomiting, diarrhea, or heartburn may […]

Read more
18Nov

Consent to the Distribution of New Medicines – 2021-go4956

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Consent to the Distribution of New Medicines – 2021-go4956

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto: Schedule Product: Ofev Active Ingredient: […]

Read more
18Nov

Trial Shows Fasting-Mimicking Diet May Boost Antitumor Immunity in Cancer Patients

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Trial Shows Fasting-Mimicking Diet May Boost Antitumor Immunity in Cancer Patients

A clinical trial in cancer patients has demonstrated that a diet involving cycles of short-term, severe calorie restriction—referred to as a fasting-mimicking diet (FMD)—can be safe, feasible, and may boost the antitumor activity of standard anticancer therapies. The trial, reported in Cancer Discovery, found that cyclic fasting resulted in a decrease in blood glucose and […]

Read more
Tags:
11Nov

Treatment of Idiopathic Pulmonary Fibrosis with Capsule or Tablet Formulations of Pirfenidone in the Real-Life French RaDiCo-ILD Cohort

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Treatment of Idiopathic Pulmonary Fibrosis with Capsule or Tablet Formulations of Pirfenidone in the Real-Life French RaDiCo-ILD Cohort

Introduction: Pirfenidone, an antifibrotic medication for idiopathic pulmonary fibrosis (IPF), is now available in France in two formulations: tablets since April 2018, and the initial capsules form. We conducted a cohort study to describe tolerance and acceptability of capsules and/or tablets of pirfenidone in patients with IPF. Methods: This study was nested within the French, […]

Read more
11Nov

Treatment of Persistent Erythema Multiforme With Janus Kinase Inhibition and the Role of Interferon Gamma and Interleukin 15 in Its Pathogenesis | Dermatology | JAMA Dermatology

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Treatment of Persistent Erythema Multiforme With Janus Kinase Inhibition and the Role of Interferon Gamma and Interleukin 15 in Its Pathogenesis | Dermatology | JAMA Dermatology

Key Points Questions  Is Janus kinase (JAK) inhibition effective for persistent erythema multiforme (PEM), and what are the important molecular targets? Findings  Four patients with PEM treated with JAK inhibition experienced marked clinical improvement, while RNA sequencing and proteomic evaluation in a single patient before and during treatment revealed that interferon gamma (IFN-γ) and interleukin […]

Read more
7Nov

Substantial Improvement in Vitiligo With Topical JAK Inhibitor

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Substantial Improvement in Vitiligo With Topical JAK Inhibitor

NEW YORK CITY — Almost 30% of patients with vitiligo had at least 75% improvement in facial involvement after 6 months of treatment with a topical formulation of the Janus kinase (JAK) inhibitor ruxolitinib (Opzelura), two randomized trials showed. The vehicle-controlled trials yielded identical primary-outcome results, as 29.9% of ruxolitinib-treated patients in each trial met […]

Read more
5Nov

The Role of In Vitro Detection of Drug-Specific Mediator-Releasing Cells to Diagnose Different Phenotypes of Severe Cutaneous Adverse Reactions

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on The Role of In Vitro Detection of Drug-Specific Mediator-Releasing Cells to Diagnose Different Phenotypes of Severe Cutaneous Adverse Reactions

This article was originally published here Allergy Asthma Immunol Res. 2021 Nov;13(6):896-907. doi: 10.4168/aair.2021.13.6.896. ABSTRACT PROPOSE: The purpose of this study was to investigate panels of enzyme-linked immunospot assays (ELISpot) to detect drug-specific mediator releasing cells for confirming culprit drugs in severe cutaneous adverse reactions (SCARs). METHODS: Frequencies of drug-induced interleukin-22 (IL-22)-, interferon-gamma (IFN-γ)-, and […]

Read more
3Nov

Host genetics but not commensal microbiota determines the initial development of systemic autoimmune disease in BXD2 mice

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Host genetics but not commensal microbiota determines the initial development of systemic autoimmune disease in BXD2 mice

This article was originally published here Arthritis Rheumatol. 2021 Nov 1. doi: 10.1002/art.42008. Online ahead of print. ABSTRACT OBJECTIVE: To determine the extent of gut microbiome in influencing systemic autoimmunity, we generated germ-free (GF) BXD2 lupus mice, which otherwise develop spontaneous germinal centers (GCs) and high titers of serum autoantibodies. METHODS: The GF status was […]

Read more
2Nov

Pirfenidone and Nintedanib Result in Similar Outcomes in IPF Patients

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Pirfenidone and Nintedanib Result in Similar Outcomes in IPF Patients

A team of German researchers compared 2 antifibrotic drugs commonly prescribed for idiopathic pulmonary fibrosis (IPF), pirfenidone and nintedanib, and discovered that patient-related parameters such as mortality, hospitalization, and costs did not differ significantly between them, according to a paper published in Respiratory Research. The researchers wrote, “Both drugs have been shown to slow IPF […]

Read more
31Oct

Three patients with defects in interferon gamma receptor signaling: a challenging diagnosis

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Three patients with defects in interferon gamma receptor signaling: a challenging diagnosis

Three patients with defects in interferon gamma receptor signaling: a challenging diagnosis Abstract Background: Defects in IFN–gamma receptor (IFN-γR) signaling via STAT1 leads to susceptibility to infection by otherwise weak pathogenic mycobacteria, resulting in mendelian susceptibility to mycobacterial disease. We identified three patients presented with disseminated mycobacterial infections caused by M. avium, M. persicum or […]

Read more
29Oct

Detection of circulant tumor necrosis factor-alpha , soluble tumor necrosis factor p75 and interferon-gamma in Brazilian patients with dengue fever and dengue hemorrhagic fever

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Detection of circulant tumor necrosis factor-alpha , soluble tumor necrosis factor p75 and interferon-gamma in Brazilian patients with dengue fever and dengue hemorrhagic fever

Pro-inflammatory cytokines are believed to play an important role in the pathogenesis of dengue infection. This study reports cytokine levels in a total of 54 patients examined in Recife, State of Pernambuco, Brazil. Five out of eight patients who had hemorrhagic manifestations presented tumor necro… Descripción completa Detalles Bibliográficos Autores: Braga,Elzinandes LA, Moura,Patrícia, Pinto,Luzia MO, […]

Read more
29Oct

Recent trends in pirfenidone and nintedanib use for idiopathic pulmonary fibrosis in Australia

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Recent trends in pirfenidone and nintedanib use for idiopathic pulmonary fibrosis in Australia

ObjectivesIdiopathic pulmonary fibrosis (IPF) is one of the most common forms of interstitial lung disease presenting in people aged ≥50 years. There is currently no cure for IPF, but two medications (pirfenidone and nintedanib) have been shown to slow the functional decline of the lungs. In 2017, these two medications were listed on the Pharmaceutical […]

Read more
29Oct

Combivent Respimat and pirfenidone Interactions

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Combivent Respimat and pirfenidone Interactions

This report displays the potential drug interactions for the following 2 drugs: Combivent Respimat (albuterol/ipratropium) pirfenidone Edit list (add/remove drugs) Interactions between your drugs No interactions were found between Combivent Respimat and pirfenidone. This does not necessarily mean no interactions exist. Always consult your healthcare provider. Combivent Respimat A total of 467 drugs are known […]

Read more
28Oct

Anti-IFN-gamma (human), clone ANC2E11, Biotin conjugated | Ancell

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Anti-IFN-gamma (human), clone ANC2E11, Biotin conjugated | Ancell

Product information “Anti-IFN-gamma (human), clone ANC2E11, Biotin conjugated” The cytokine human interferon-gamma (IFN-gamma) is a glycosylated protein that exists as a homodimer of 34kDa in its biologically active form. IFN-gamma is expressed upon activation by TH1 cells CD8 cells and NK cells. Secreted IFN-gamma is a potent inhibitor of in vitro hematopoiesis and appears to […]

Read more
26Oct

Integrated Headquarters Of Ministry Of Defence Latest Tenders

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Integrated Headquarters Of Ministry Of Defence Latest Tenders

Tenders for Integrated Headquarters Of Ministry Of Defence 3 tenders available for Integrated Headquarters Of Ministry Of Defence from state, central, railways, GEM and all other government orgs (eprocure portals) across india. Complete Integrated Headquarters Of Ministry Of Defence tender details and Integrated Headquarters Of Ministry Of Defence tender notices (NIT) are available for free […]

Read more
21Oct

Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study

Data set and sample selection We performed a retrospective cohort study with health insurance claims data of the Allgemeine Ortskrankenkasse (AOK) provided by the AOK Research Institute. AOK provides statutory health insurance for roughly 32 percent of the German population [16]. Membership is open to anyone regardless of factors such as professional affiliation, income, age or […]

Read more
17Oct

Simple Plex Control for Human IFN-gamma (899077)

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Simple Plex Control for Human IFN-gamma (899077)

Simple Plex Control for Human IFN-gamma Summary INTENDED USE AND DESCRIPTION: For use a quantitative control for the determination of human IFN-gamma concentrations in biological fluids. Controls are supplied lyophilized. Please refer to the lot specific certificate of analysis and Simple Plex Lyophilized Quality Control product insert for additional information. IFN-gamma (Interferon-gamma) is the prototype […]

Read more
15Oct

Potential treatment for vocal fold scar with pirfenidone.

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Potential treatment for vocal fold scar with pirfenidone.

Pirfenidone (PFD) is a strong antifibrotic agent that has been clinically approved in Japan for idiopathic pulmonary fibrosis. We examined the antifibrotic effects of PFD on fibroblasts isolated from scarred vocal folds (VFs) of ferrets in vitro. Prospective animal experiments with controls. Scar fibroblasts (SFs) were isolated from scarred VFs that had been electrocauterized 2 weeks […]

Read more
« Older posts
Newer posts »